Navigation Links
Pain-killer Drug Can Help Fight Breast Cancer

A new study using tissue cultures suggests, that a pain killing medication helps by halting the production of an enzyme that is key to a common form of breast cancer. The name of the painkiller is Nimesulide. //

In the labs experiments on breast cancer cells, scientists found that derivatives of nimesulide stopped the production of aromatase, the enzyme implicated in estrogen-dependent breast cancer. This form of cancer is the most common breast cancer in postmenopausal women. Aromatase converts hormones called androgens into estrogens, Estrogen is a powerful mitogen, which is an agent that causes cells to divide, and too much estrogen can cause cells to divide too quickly.

Robert Brueggemeier, professor of medicinal chemistry and pharmacognosy and dean of the College of Pharmacy at Ohio State University, and the co-author of the study states that many women with estrogen-dependent breast cancer take aromatase inhibitors to control their disease, the problem is that the current inhibitor drugs halt estrogen production throughout the body. Meaning that other parts like bones and brains, which need normal aromatase production, might suffer.

The results suggest that nimesulide may block aromatase production only in breast tissue. Nimesulide is a non-steroidal anti-inflammatory drug (NSAID), used for pain and inflammation. Studies of other NSAIDs, such as ibuprofen, have suggested that NSAIDs may reduce breast cancer incidence by 40 percent. They said that by altering certain basic chemical structure of the drug, they could create several variations or analogs, of nimesulide. Nimesulide was banned from clinical and over the counter use in the United States due to rare cases of liver damage and related deaths.

The researchers took several of these analogs and in laboratory cultures, tested their effects on estrogen-dependent breast cancer cells taken from human breast tissue. They also tested them on human placental cells to see if the analogs would stop aromatase production in these cells. They found that the analogs stopped aromatase production in the breast cells, but not in the placental cells.

Brueggemeierm, stated that aromatase is important for normal functions of many tissues in the body, they still had to test it on other tissues. He further stated that the next step would be to see and study how the analogs affect other types of tissues to make sure that nimesulides aromatase-inhibiting effects are truly isolated to breast tissue. And then to learn how effective these compounds are when they are actually inside the body and what the potential side effects may be.


'"/>




Related medicine news :

1. Fight Heart disease and Pain with Meditation
2. Fight anemia by fortifying crops with iron!!!!!!!!
3. Fight arthritic pain with acupuncture
4. Smallpox Vaccine May Help Fight Cervical Cancer
5. Fight against E.coli
6. Red Wine Helps Fight Heart disease
7. Fish Oil Fights Arrhythmias, Sudden Death
8. SARS-Free Taiwan to Mark End Phase of Global Fight
9. Few Parents Help Kids Fight Acne
10. Common Cold Found to Fight Cancer
11. The Possibility Of Fighting HIV with Another Virus Questioned
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... at the University of California Berkeley, and other leading institutions in announcing the ... power of institutions to change the way animals are raised for food. , ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
Breaking Medicine Technology: